Title: Clinical response to lumacaftor-ivacaftor in patients with cystic fibrosis according to baseline lung function.

Authors: Pierre-Régis BURGEL MD 1,2,3, Isabelle DURIEU MD 3,4,5, Raphaël CHIRON MD 6, Laurent MELY MD 7, Anne PREVOTAT MD 8, Marlene MURRIS-ESPIN MD 9, Michele PORZIO MD 10, Michel ABELY MD 11, Philippe REIX MD 12, Christophe MARGUET MD 13, Julie MACEY MD 14, Isabelle SERMET-GAUDELUS MD 3,15,16, Harriet CORVOL MD 17, Stéphanie BUI MD 18, Tiphaine BIOUHEE MD 19, Dominique HUBERT MD 2,3, Anne MUNCK MD 20, Lydie LEMONNIER PhD 21, Clémence DEHILLOTTE PhD 21, Jennifer DA SILVA BS 1,3,22 Jean-Louis PAILLASSEUR PhD 23, Clémence MARTIN MD 1,2,3 for the French Cystic Fibrosis Reference Network study group

Affiliations: French Cystic Fibrosis Reference Network study group, Paris, France

What was your research question?
Our aim was to evaluate safety and effectiveness of lumacaftor-ivacaftor according to baseline lung function.

Why is this important?
Lumacaftor-ivacaftor (LUMA-IVA), a combination of CFTR modulators, is now licensed in many countries for people homozygous for the Phe508del CFTR mutation, who represent 40-50% of people with CF worldwide. Initial phase 3 clinical trials were undertaken in people with CF aged 12 years and older with a percent predicted forced expiratory volume in one second (ppFEV1) between 40 and 90. Nonetheless, LUMA-IVA was approved for Phe508del homozygous individuals at all levels of ppFEV1 by regulatory agencies in the US and in Europe. Few data exist on 1-year safety and effectiveness in people with ppFEV1<40 or ≥90.

What did you do?
The present study used data collected in a large cohort of people aged 12 years and older who started LUMA-IVA in 2016 in France, in order to examine its safety and effectiveness at different levels of baseline ppFEV1 over the first year of treatment. Among the 845 individuals who initiated LUMA-IVA in 2016, one third of those had a ppFEV1 at baseline that would have been considered either too low (ppFEV<40) or too high (ppFEV≥90) to meet eligibility criteria for phase 3 clinical trials, which included only people with ppFEV1 [40-90].
What did you find?
A ppFEV₁ increase ≥5% was found in 40% of people with baseline ppFEV₁ [40-90], a proportion that was 1.5 to 2-fold higher than in those with baseline ppFEV₁ <40 or ppFEV₁≥90. Improvement in body mass index (BMI) was found in all individuals, and the magnitude of improvement was comparable across all subgroups. The number of intravenous (IV) antibiotic days per year was also reduced in all subgroups, but the effects of LUMA-IVA on exacerbation rates appeared less robust in people with severe respiratory damage. As expected, respiratory adverse events occurred more often in those with more severe respiratory disease.

What does this mean and reasons for caution?
The present analysis indicates that adolescents and adults with CF may benefit from LUMA-IVA at all levels of baseline lung function. Findings that the subgroup of people with ppFEV₁<40 were at higher risk of adverse effects, and that both subgroups of patients with ppFEV₁<40 or with ppFEV₁≥90 showed less consistent improvement in lung function concur with the choice of limiting recruitment in phase 3 clinical trials to people with ppFEV₁ [40-90]. Importantly, at the individual level, those with ppFEV₁<40 or ppFEV₁≥90 could show a significant improvement in ppFEV₁ after initiation of CFTR modulator therapy.

What’s next?
These findings reinforce the decision from regulatory agencies to grant treatment indication to all people with eligible CFTR genotypes, regardless of baseline lung function.

Original manuscript citation in PubMed